Panelists discuss how novel intravitreal agents faricimab and high-dose aflibercept 8mg offer potential advantages in treating retinal diseases through their extended durability and dual mechanism of ...

Panelists discuss how ideal candidates for aflibercept 8 mg include patients with stable disease on current anti-VEGF therapy who seek reduced treatment burden, newly diagnosed patients, and those ...

Panelists discuss how careful patient selection and management of potential complications - including surgical risks, device-related adverse events, and cost-benefit considerations requiring operating ...

Panelists discuss how faricimab’s bispecific antibody design uniquely targets both VEGF-A and Ang-2 pathways, addressing the complementary role of Ang-2 in vascular destabilization and inflammation in ...

The Sentinel Camera aims to address critical gaps in retinal disease screening by offering a portable device that captures high-quality images that require no dilation of the eye. AI Optics, an ...

Previous research has shown that voretigene neparvovec administered subretinally early in childhood for RPE65-mediated inherited retinal dystrophy achieved encouraging efficacious results. Treatment ...

Dr Jordan Graff highlights key steps in implanting the port delivery system, emphasizing incision and closure techniques with video clips.

Panelists discuss how the port delivery system (PDS) refill procedure, while performed in an office setting, involves a different technique of accessing and replenishing the implant’s drug reservoir ...

A large study that retrospectively analyzed the visual outcomes and rate of development of neovascular age-related macular degeneration (nAMD) in eyes with geographic atrophy (GA) found that GA can ...

Investigators from the Cleveland Clinic Cole Eye Institute, Cleveland, reported the results of a study that identified macular structural and vascularity changes in adults who had been born ...

Panelists discuss how the Port Delivery System (PDS) presents important considerations around adverse effects, patient selection criteria, and adoption challenges including surgical requirements and ...

Apellis has announced the Therapeutic Goods Administration (TGA) in Australia has approved pegcetacoplan (Syfovre) for the every-other-month treatment of adult patients with geographic atrophy (GA) ...